Provided by Tiger Fintech (Singapore) Pte. Ltd.

Urogen Pharma Ltd.

11.07
+0.17001.56%
Post-market: 11.070.00000.00%19:31 EDT
Volume:272.43K
Turnover:3.02M
Market Cap:510.26M
PE:-3.74
High:11.23
Open:10.95
Low:10.91
Close:10.90
Loading ...

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
18 Feb

UroGen announces results from subgroup analyses of ENVISION trial

TIPRANKS
·
15 Feb

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
12 Feb

UroGen Pharma announces results from long-term Jelmyto follow-up study

TIPRANKS
·
12 Feb

UroGen Pharma reports ENVISION results to be published in The Journal of Urology

TIPRANKS
·
15 Jan

Further weakness as UroGen Pharma (NASDAQ:URGN) drops 10% this week, taking five-year losses to 67%

Simply Wall St.
·
15 Jan

Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)

Simply Wall St.
·
31 Dec 2024

UroGen Pharma presents long-term, follow-up Jelmyto study data

TIPRANKS
·
06 Dec 2024

UroGen Pharma: UGN-102 showed ‘promising’ results in Phase 3 Envision trial

TIPRANKS
·
06 Dec 2024

UroGen Pharma Says Jelmyto Chemoablation Shows Long-Term Duration of Response in Urothelial Cancer Patients

MT Newswires Live
·
26 Nov 2024

UroGen Pharma publishes long-term Jelmyto follow-up study results

TIPRANKS
·
26 Nov 2024

Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?

Simply Wall St.
·
18 Nov 2024

UroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

GuruFocus.com
·
07 Nov 2024

Urogen Pharma (URGN) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
06 Nov 2024

UroGen Pharma Q3 2024 GAAP EPS $(0.55) Beats $(0.83) Estimate, Sales $25.20M Beat $24.20M Estimate

Benzinga
·
06 Nov 2024

Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years

Simply Wall St.
·
19 Oct 2024